Dean is a leading patent strategist in the life sciences sector who works with biotechnology and pharmaceutical companies at all stages of development. His clients range from start-ups, to mid-size pharmas with NCEs entering clinical trials, to large companies with vast patent portfolios.
Dean’s years working in the industry and two decades in patent law position him as a strategic partner for his clients. He helps them understand the risks and opportunities associated with various approaches to protecting their innovations and helps them develop and implement strategies centered on their business goals. Dean handles patent procurement, portfolio management, IP due diligence, and opinions including freedom-to-operate, validity, and patentability assessments in the areas of chemistry, pharmaceuticals, and biotechnology. With deep experience in business, chemistry, and IP law, he understands the business risks and complexities facing companies in the biopharmaceutical sector in ways that others lacking his unique combination of perspectives cannot — and leverages his exceptional insight to help clients navigate IP risks and shifting industry challenges.
He is recognized as a leading patent lawyer by Legal 500 and IAM Patent 1000 and has been a recipient of the Healthcare & Life Sciences – Massachusetts Client Choice Award.
Dean’s work as a scientist focused on synthetic organic chemistry, drug/nucleic acid interactions, drug/protein interactions, and complex target protein interactions. He earned his PhD in Organic Chemistry at Brown University, where he worked in the lab of Bill Suggs and was awarded the AT&T–Brown Faculty Scientific Achievement Award. He then studied with Stuart Schreiber at Harvard University as an American Cancer Society postdoctoral fellow and recipient of the NIH postdoctoral fellowship.
Dean’s thesis work was directed to the total synthesis (14 steps) of dimeric-anthramycin analogs and the study of their DNA binding specificity. Representative of his work in the Schreiber laboratories is the publication in 1991 that small molecules FK506 and cyclosporin inhibit the activity of the phosphatase calcineurin by forming the ternary complexes FKBP12-FK506-calcineurin and cyclophilin-cyclosporin-calcineurin (Liu J, Farmer JD, Lane WS, Friedman J, Weissman I, Schreiber SL, “Calcineurin is a common target of cyclophilin-cyclosporin A and FKBP-FK506 complexes,” Cell 66 (4): 807–15, Schreiber’s most cited work to date.
